{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:39:36Z","timestamp":1707525576690},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,6]]},"DOI":"10.7759\/cureus.50063","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T20:19:54Z","timestamp":1701893994000},"source":"Crossref","is-referenced-by-count":0,"title":["The Challenge of Managing Refractory Psychosis Amid Multiple Medication Side Effects: A Case Report and Review of the Literature"],"prefix":"10.7759","author":[{"given":"Alejandro","family":"Rodulfo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zina","family":"Meriden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62036-X","article-title":"Schizophrenia: an integrated sociodevelopmental-cognitive model","volume":"383","author":"Howes OD","year":"2014","unstructured":"Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet. 2014, 383:1677-87. 10.1016\/S0140-6736(13)62036-X","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology","volume":"174","author":"Howes OD","year":"2017","unstructured":"Howes OD, McCutcheon R, Agid O, et al.. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry. 2017, 174:216-29. 10.1176\/appi.ajp.2016.16050503","journal-title":"Am J Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay SR","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987, 13:261-76. 10.1093\/schbul\/13.2.261","journal-title":"Schizophr Bull"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2018.08.016","article-title":"Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives","volume":"131","author":"Nucifora FC Jr","year":"2019","unstructured":"Nucifora FC Jr, Woznica E, Lee BJ, Cascella N, Sawa A. Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2019, 131:104257. 10.1016\/j.nbd.2018.08.016","journal-title":"Neurobiol Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1176\/appi.focus.20200025","article-title":"Treatment-resistant schizophrenia","volume":"18","author":"Buckley PF","year":"2020","unstructured":"Buckley PF. Treatment-resistant schizophrenia. Focus (Am Psychiatr Publ). 2020, 18:364-7. 10.1176\/appi.focus.20200025","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup TS","year":"2018","unstructured":"Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018, 17:341-56. 10.1002\/wps.20567","journal-title":"World Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-12-20","article-title":"A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia","volume":"12","author":"Dibonaventura M","year":"2012","unstructured":"Dibonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012, 12:20. 10.1186\/1471-244X-12-20","journal-title":"BMC Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","article-title":"","year":"2013","unstructured":"Diagnostic and Statistical Manual of Mental Disorders.  American Psychiatric Association, 2013. 10.1176\/appi.books.9780890425596"},{"key":"ref9","article-title":"Medication-induced tardive dyskinesia: a review and update","volume":"17","author":"Cornett EM","year":"2017","unstructured":"Cornett EM, Novitch M, Kaye AD, Kata V, Kaye AM. Medication-induced tardive dyskinesia: a review and update\r\n. Ochsner J. 2017, 17:162-74.","journal-title":"Ochsner J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000326","article-title":"Real-world experience with VMAT2 inhibitors","volume":"42","author":"Niemann N","year":"2019","unstructured":"Niemann N, Jankovic J. Real-world experience with VMAT2 inhibitors. Clin Neuropharmacol. 2019, 42:37-41. 10.1097\/WNF.0000000000000326","journal-title":"Clin Neuropharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.9.1451","article-title":"Antipsychotic-induced extrapyramidal symptoms and their management","volume":"9","author":"Dayalu P","year":"2008","unstructured":"Dayalu P, Chou KL. Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opin Pharmacother. 2008, 9:1451-62. 10.1517\/14656566.9.9.1451","journal-title":"Expert Opin Pharmacother"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4646-1","article-title":"Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment","volume":"234","author":"Juncal-Ruiz M","year":"2017","unstructured":"Juncal-Ruiz M, Ramirez-Bonilla M, Gomez-Arnau J, et al.. Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment. Psychopharmacology (Berl). 2017, 234:2563-70. 10.1007\/s00213-017-4646-1","journal-title":"Psychopharmacology (Berl)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107086516","article-title":"Clinical questions and uncertainty--prolactin measurement in patients with schizophrenia and bipolar disorder","volume":"22","author":"Walters J","year":"2008","unstructured":"Walters J, Jones I. Clinical questions and uncertainty--prolactin measurement in patients with schizophrenia and bipolar disorder. J Psychopharmacol. 2008, 22:82-9. 10.1177\/0269881107086516","journal-title":"J Psychopharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1116","article-title":"Hyperprolactinemia associated with psychotropics--a review","volume":"25","author":"Madhusoodanan S","year":"2010","unstructured":"Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics--a review. Hum Psychopharmacol. 2010, 25:281-97. 10.1002\/hup.1116","journal-title":"Hum Psychopharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3928\/00485713-20150501-09","article-title":"Guidelines for antipsychotic-induced hyperprolactinemia","volume":"45","author":"Miyamoto B","year":"2015","unstructured":"Miyamoto B, Galecki M, Francois D. Guidelines for antipsychotic-induced hyperprolactinemia. Psychiatr Ann. 2015, 45:266-8. 10.3928\/00485713-20150501-09","journal-title":"Psychiatr Ann"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/2045125316641019","article-title":"Clozapine-induced hypersalivation: an estimate of prevalence, severity and impact on quality of life","volume":"6","author":"Maher S","year":"2016","unstructured":"Maher S, Cunningham A, O'Callaghan N, Byrne F, Mc Donald C, McInerney S, Hallahan B. Clozapine-induced hypersalivation: an estimate of prevalence, severity and impact on quality of life. Ther Adv Psychopharmacol. 2016, 6:178-84. 10.1177\/2045125316641019","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E077","article-title":"Intraoral application of atropine sulfate ophthalmic solution for clozapine-induced sialorrhea","volume":"38","author":"Sharma A","year":"2004","unstructured":"Sharma A, Ramaswamy S, Dahl E, Dewan V. Intraoral application of atropine sulfate ophthalmic solution for clozapine-induced sialorrhea. Ann Pharmacother. 2004, 38:1538. 10.1345\/aph.1E077","journal-title":"Ann Pharmacother"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12028ah1","article-title":"Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice","volume":"74","author":"Newcomer JW","year":"2013","unstructured":"Newcomer JW, Weiden PJ, Buchanan RW. Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice. J Clin Psychiatry. 2013, 74:1108-20. 10.4088\/JCP.12028ah1","journal-title":"J Clin Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/169290-the-challenge-of-managing-refractory-psychosis-amid-multiple-medication-side-effects-a-case-report-and-review-of-the-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:08:00Z","timestamp":1707509280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/169290-the-challenge-of-managing-refractory-psychosis-amid-multiple-medication-side-effects-a-case-report-and-review-of-the-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.50063","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,6]]}}}